chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pain in neck beginning approximately one week after vaccine; hypertrophic change in C1-C2 joint; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 33-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 25May2021 as dose 1, single (Batch/Lot number: unknown) at the age of 32 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: NECK PAIN (non-serious) with onset 02Jun2021, outcome "not recovered", described as "Pain in neck beginning approximately one week after vaccine"; SPINAL OSTEOARTHRITIS (non-serious) with onset 02Jun2021, outcome "not recovered", described as "hypertrophic change in C1-C2 joint". The events "pain in neck beginning approximately one week after vaccine" and "hypertrophic change in c1-c2 joint" required physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of neck pain, spinal osteoarthritis.   Additional information: Pain in neck beginning approximately one week after vaccine. MRI results show hypertrophic change in C1-C2 joint. No injury or other reason for this change. Second dose given on 28Aug2021 on Left arm, Lot number: EWU179. Treatment received as Physical therapy, chiropractic treatment, MRI.    The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201006603 Same product, patient, different AEs, different dose;
ACUTE RESPIRATORY FAILURE ACUTE HYPOXEMIC RESPIRATORY FAILURE ACUTE PULMONARY EMBOLISM CHRONIC HYPOXEMIC RESPIRATORY FAILURE ACUTE ON CHRONIC RESPIRATORY FAILURE HYPOXEMIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY HYPOXIA 12/20/2022 &  2/10/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
This case was reported by a physician via sales rep and described the occurrence of injection site pain in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced injection site pain, injection site erythema, injection site swelling, injection site rash and injection site warmth. On an unknown date, the outcome of the injection site pain, injection site erythema, injection site swelling, injection site rash and injection site warmth were unknown. It was unknown if the reporter considered the injection site pain, injection site erythema, injection site swelling, injection site rash and injection site warmth to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient experienced pain, redness, swelling, rash, and heat at injection site.
Felt nothing when i got the shot. After a day or two there was tenderness and redness about 2" in diameter and a firm area under skin. Appeared worse after a week and became itchy.  Had it looked at on 08/17 at Dr's office and no sign of infection. Still red and firm, no open area. Started to look like a scab under skin, covered with coco oil and a bandaid to soften because it was itchy and i scratched scab edge. No bleeding. I think when scab dried it became itchy and i scratched it again, more came up around edge. Now there is a crater with another scab that is 1/2" in size with a firm, tender area below it.
I had deep chest congestion. Strong body aches with a mild headache. Weakness and very fatigue. Still experiencing fatigue and some dizziness lately, balance issues. I got tendinous really bad.
Vaccine stored in refrigerator on 11-Jul-2022/Vaccine administered on 13-Aug-2022; No adverse event; Patient administered vaccine from a vial that was beyond the 30-day use by date; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient administered vaccine from a vial that was beyond the 30-day use by date), PRODUCT STORAGE ERROR (Vaccine stored in refrigerator on 11-Jul-2022/Vaccine administered on 13-Aug-2022) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Spikevax) (batch no. AR4504B) for COVID-19 vaccination.     No Medical History information was reported.    On 13-Aug-2022, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 13-Aug-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient administered vaccine from a vial that was beyond the 30-day use by date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine stored in refrigerator on 11-Jul-2022/Vaccine administered on 13-Aug-2022) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient administered vaccine from a vial that was beyond the 30-day use by date), PRODUCT STORAGE ERROR (Vaccine stored in refrigerator on 11-Jul-2022/Vaccine administered on 13-Aug-2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Patient administered vaccine from a vial that was beyond the 30-day use by date) and PRODUCT STORAGE ERROR (Vaccine stored in refrigerator on 11-Jul-2022/Vaccine administered on 13-Aug-2022).    No concomitant medications were reported.  The reporter wanted to know if the dose was stable and whether or not had to re-dose.   Number of doses or vials was 1 dose or 1 vial. The vial was initially stored in the refrigerator on 11-Jul-2022. The vial did not undergo any temperature excursions.  No treatment medications were reported.
Second day soreness and redness at site that got worse traveled into the arm, to the shoulder and up into the neck, all happened over a 3 week period. Still have pain in right side of neck, arm has pain to the touch and when laid on.  Hurts to pick anything up. Pain traveled from injection site into the shoulder, slight swelling in the neck area. Still having pain.
Information has been received from a physician concerning his 12 year old daughter with eczema and seasonal allergies who on an unspecified date was vaccinated intramuscularly into her arm with a first dose of GARDASIL (Lot# unknown). The physician reported that her daughter was given GARDASIL by a pediatrician and on an unspecified date, she experienced redness and swelling in her arm, up her neck and toward her face. Therapy with GARDASIL was discontinued. At the time of the report, the patient had recovered (date unknown). The patient sought unspecified medical attention. No further information is available.
While waiting after vaccine patient reported feeling woozy. She was assessed and BP was 162/82, HR 60, Lung sounds clear. After waiting with EMT for 20 minutes, she sat for approximately 20 more minutes in clinic, then felt better. She did not wish to have another BP done. She left.
Brain fog/disorientation (felt like I was intoxicated for about 48 hours, which got slowly better after that) and lethargy.
Information has been received through the Merck pregnancy registry from a nurse concerning a 29 year old female consumer with hepatitis b positive and pineapple allergy who on 24-MAR-2008 was vaccinated SQ with one dose of 0.5ml of VARIVAX (Oka/Merck) (lot # 659607/1760U).  Suspect vaccination included MMR II (Enders-Edmonston, Jeryl Lynn, Wistar RA 27/3).  Concomitant vaccination included DTaP.  The nurse reported that the patient is now pregnant.  The patient's LMP was reported as 18-FEB-2008.  Medical attention was sought, the patient called the office.  A urine pregnancy test confirmed the pregnancy.  No symptoms were reported.  It was noted that the patient was to schedule an appointment with the physician.  At the time of the report the outcome of the pregnancy was unknown.  There was no product quality complaint involved.  Additional information has been requested.  Additional information has been received which reported that the patient had a spontaneous abortion on 09-Apr-2008 (7 weeks from the patient's LMP).  The lot number for DTaP was reported as PMCC02775AA.  It was reported that no other medications were used during this pregnancy.  Upon internal review, it was determined that spontaneous abortion was an other important medical event.
FLUSH; MILD FLU LIKE SYMPTOMS; CHILLS; This spontaneous report received from a patient concerned a 50 year old of unspecified sex. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 202A21A, and batch number: 202A21A expiry: UNKNOWN) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced flush. On APR-2021, the subject experienced mild flu like symptoms. On APR-2021, the subject experienced chills. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from flush, mild flu like symptoms, and chills on APR-2021. This report was non-serious.
Information has been received from a bachelor of science in nursing concerning a 16 year old female with no pertinent medical history and codeine allergy who on 14-DEC-2006 was vaccinated with the first dose of GARDASIL vaccine (yeast) 0.5 ml IM (lot # 654885/1424F). Concomitant therapy included SUDAFED and DELSYM. On 14-DEC-2006 the patient experienced injection site reaction, arm red, swollen and warm from shoulder to the elbow for 5 days after the injection. Subsequently, the patient recovered from injection site reaction, arm red, swollen and warm from shoulder to the elbow. The patient did not contact the physician at the time of the events. Additional information has been requested.
Tinnitus  7 days after first dose...lasted one night. Tinnitus 13 days after second dose that is still a problem 8 days later.
onset 18FEB99 24hr p/vax has erythema extending 10cm & 6cm from site to DTAP inj downward;1cm x 1cm area of erythematous;no tenderness;
shingles; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (shingles) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced HERPES ZOSTER (shingles). At the time of the report, HERPES ZOSTER (shingles) outcome was unknown.            Concomitant product use was not provided by the reporter. Treatment information was not provided.  Action taken with mRNA-1273 in response to the events was not Applicable.
GUILLAIN BARRE SYNDROME; SICK; A spontaneous report has been received from a consumer. The report concerns a female patient (age not provided) of unknown ethnic origin.    No medical history was reported. The following demography was reported for the patient's parent: Sex: Unknown    No concomitant products were reported.    On an unknown date, the patient received Flumist (influenza virus vaccine live, intranasal) once/single administration, via nasal route, for an unknown indication.     Reporter stated that patient developed Guillain Barre syndrome (preferred term: Guillain-Barre syndrome) immediately after shot also she got sick (preferred term: Illness) after your shot.    At the time of the report, the outcome of the events of guillain barre syndrome and sick was unknown.    The company physician assessed the event guillain barre syndrome as serious due to important medical event criterion.    The company physician assessed the event sick to be non-serious.
Loss of hearing in my left ear along with chronic tinnitus which all started days after the injection.
Case number PHEH2011US01756 is an initial spontaneous report received from a health care professional on 03 Aug 2011. This report refers to an adolescent female patient. She was given only the MenA powder conjugate component of MENVEO (batch number: A10059 and expiry date: Jan 2013) reconstituted with a sterile diluent instead of MenCWY liquid conjugate component intramuscularly on 13 Jul 2011. No other adverse reaction was reported.
May 5 ,2021 patient became dizzy, diarrhea, syncopal poor appetite, feeling lethargic, having chills.  "I couldn't keep anything down"
She received a Tdap, MCV40 injection on 4/16/14. The next morning mom noticed that the area was red, it hurt to touch the area. The redness continues to spread so mom brought her in to the clinic on 4/18/14. She had a 7cm x 7cm area of erythema , warmth, induration on her (L) arm in the deltoid region at the injection site. Mild pain with palpation. She was told to return to the clinic if sx got worse or didn't improve.
01/14/22 presents to ED for "Wound Infection". PMHx  of "Type II DM on Insulin, CKD, and currently COVID +"
Patient reported on 2/10/2020 that 2 hours after receiving the injection on 2/4/20 he felt sick and then it got worse over the next two days. Patient states chills, fever, increased phlegm, difficulty breathing (requiring use of nebulizer) coughing and rectal bleeding. He reported this to the patient relations staff on 02/10/20, who in turn gave it to me to complete the VAERS.
tested positive for Covid; This is a spontaneous report from a Pfizer sponsored program COVAX US Support. A contactable female consumer (patient) reported for herself that. A female patient of an unspecified age received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, solution for injection), dose 1 via an unspecified route of administration on 22Jul2021 (Batch/Lot number was not reported) as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history was not reported.  The patient's concomitant medications were not reported. It was reported that patient received the first dose of vaccine last 22Jul2021 and tested positive for Covid last 30Jul2021. Patient asked when her schedule was to receive the second dose. Outcome of the event was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Possible Pityriasis Rosea.  Hd a "herald patch" first on left upper arm.   First rash was on legs, which disappeared the following day.  Currenlty have red measle like rash on torso, back, and belly.  Slightly itchy,  Have used hydrocortisone on it and taken Benedryl.    See dermatologist on April 13th.
Began with redness and swelling at site about 1 hr after injection. Tried cold compresses and Ibuprofen with no relief on 10/01/18. Patient was then seen 10/3/18 at Urgent Care. Started ZYRTEC and reaction improved day 4 after reaction.
Red rash, whelps, itching rash and whelps were in immunized arm around the elbow.
Just getting over them; Terrible pain; Felt terrible; This case was reported by a consumer via interactive digital media and described the occurrence of shingles in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine and an unknown time after starting Valacyclovir, the patient experienced shingles, pain and feels awful. The patient was treated with valaciclovir (Valacyclovir). On an unknown date, the outcome of the shingles, pain and feels awful were unknown.   It was unknown if the reporter considered the shingles, pain and feels awful to be related to Shingles vaccine.     Additional Information: GSK Receipt date: 01-MAR-2023 Reporter's Comment:  This case was reported by a patient via interactive digital media. The patient had the first shingle shot in 2019 and Just getting over them terrible pain. The patient started on valacyovir an antiviral on the 3rd day.  The patient I felt terrible the whole time he/she was on them, 3 pills a day for 7 days. The follow-up could not be possible as no contact details were available.
This spontaneous report as received from a registered nurse refers to unspecified patients. On an unknown date the patients were vaccinated with PEDVAXHIB (dose, lot #, route unknown). No concomitant medication was reported. On an unknown date the patients were inadvertently vaccinated with 3 doses of improperly stored PEDVAXHIB. No adverse events were reported. Product quality complaint was not involved. The outcome of events was unknown. This is one of several reports from the same reporter. Additional information has been requested.
Arm swollen, hard to move. Forearm hurts as well and wrist when I move my arm.
for about an hour the left side of my upper lip was swelled and was tingling and was floppy.  the very tip of my tongue was buzzy/tingly...but only lasted maybe 5 minutes or less.  I stayed awake most of the night to make sure nothing more seriously, but then feel asleep and nothing else happened.
I had a sore throat, body chills, headache, and eventually lost my taste and smell; but, I was diagnosed with a sinus infection a couple of days prior. I didn't have a fever or anything. My friend called me and informed me that they recently tested positive for COVID-19 after being around each other some days ago. I was already having symptoms, so I decided to take an at-home test on 07/14/2022 which came back negative. I later found out I completed the test wrong, so on 07/15/2022 I went to the pharmacy to take a PCR test which came back positive. They immediately prescribed me PAXLOVID and amoxicillin for my symptoms. After taking the prescriptions for about 5-6 days later, I began feeling better again.
12 hours after vaccine, patient experienced dizziness and balance problems.  unable to ambulate to the bathroom without assistance from her husband.  Also experienced cognitive delays and not able to respond to questions.  Patient stayed home and did not seek medical attention.  Her symptoms gradually resolved after 4 days.
Information has been received from a pharmacist concerning a female with diabetes who on 09-FEB-2008 was vaccinated with Zostavax (Oka/Merck).  On 12-FEB-2008 the patient experienced fever and injection site reaction.  There is no product quality complaint involved.  Additional information has been requested.  This is one of several reports from the same source.
dose received 3; Swollen Lymph Nodes in the Armpit of the Injection site arm (after 3rd dose), lasting for at least 4 days; This is a spontaneous report from a contactable consumer. A 25-year-old male patient received third dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8841) via an unspecified route of administration in the left arm on 05Nov2021 at 09:00 (at the age of 25-year-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration on 21Jan2021 (at the age of 24-year-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration on 11Feb2021 (at the age of 24-year-old), both as single dose for COVID-19 immunisation. On an unknown date in Nov2021, the patient experienced swollen lymph nodes in the armpit of the injection site arm (after third dose), lasting for at least 4 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph nodes in the armpit of the injection site arm (after third dose) was resolving at the time of this report.  No follow-up attempts are possible. No further information is expected.
ACHE-Y BACK; FEVER; EXHAUSTED; UNCOMFORTABLE; TIRED; MUSCLE ACHES; This spontaneous report received from a consumer concerned a male of unspecified age. The patient's height, and weight were not reported. The patient's past medical history included covid-19. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805029, expiry: UNKNOWN) dose was not reported, administered on 22-MAR-2021 09:30 for prophylactic vaccination. No concomitant medications were reported.  On MAR-2021, the subject experienced muscle aches. On 22-MAR-2021, the subject experienced uncomfortable. On 22-MAR-2021, the subject experienced tired. On 23-MAR-2021, the subject experienced ache-y back. On 23-MAR-2021, the subject experienced fever. On 23-MAR-2021, the subject experienced exhausted. Laboratory data included: Body temperature (NR: not provided) 101.5 F. Treatment medications (dates unspecified) included: paracetamol. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the fever, muscle aches, tired, uncomfortable, ache-y back and exhausted was not reported. This report was non-serious.
After 24 hours sever ankle pain and unable to put weight on that leg,   This occurred  on Oct 25.   Received the RSV injection on Oct 31 and the pain return and could not walk on the foot again.   About three weeks later after driving about 30 minutes, exited my car and again I could not walk on it.   There is brusing on the  bread toe and two toes next to the great toe, which migrated to the bottom of my foot and then up the inside of my ankle to the shin.
This spontaneous report was received from a pharmacist refers to a patient of unknown age. On 03-MAY-2016, the patient was vaccinated with a dose of ZOSTAVAX lot # L034727, 09-DEC-2016 inadvertently reconstituted with expired sterile diluent (L005459, 18-FEB-2016). No adverse effects reported. Additional information has been requested.